Progesterone: The Most Underrated Hormone in Women’s Health

Estrogen receives most of the attention. When women think about hormonal decline, they think about hot flashes, and hot flashes are primarily an estrogen story. When physicians prescribe hormone therapy, estrogen is typically the starting point.

Progesterone occupies a supporting role in the popular understanding of women’s hormonal health. It is framed as the hormone that maintains pregnancy, and once reproduction is no longer relevant, its importance seems to fade.

This framing is incomplete. Progesterone does far more than support pregnancy. It is central to sleep, mood stability, anxiety regulation, bone maintenance, breast health, and neuroprotection. And in perimenopause, it is often the first hormone to decline, frequently years before estrogen shows measurable change.

Progesterone Beyond Reproduction

Sleep

Progesterone metabolizes into allopregnanolone, a neurosteroid that enhances the activity of GABA-A receptors in the brain. GABA is the primary inhibitory neurotransmitter. When GABA activity is strong, the nervous system calms, the transition to sleep is smooth, and the architecture of sleep, particularly the proportion of slow-wave (deep) sleep, is preserved.

As progesterone declines in perimenopause, allopregnanolone production falls. GABA activity diminishes. Women begin waking at 2 or 3 AM, or report sleeping through the night but feeling unrestored. The sleep disruption precedes the hot flashes, sometimes by years.

Many women are prescribed sleep medications or told to improve their sleep hygiene without anyone measuring progesterone. Restoring progesterone to physiological levels often resolves the sleep disruption without any other intervention.

Anxiety and Mood

The same GABAergic mechanism that supports sleep also modulates anxiety. The calming effect of progesterone on the central nervous system is pharmacologically analogous to what benzodiazepines achieve, though through a different binding site on the same receptor.

When progesterone drops, the nervous system loses a source of tonic inhibition. Women in perimenopause frequently describe a pervasive sense of unease, an internal restlessness that was never there before. This is not psychological in origin. It is neurochemical.

New-onset anxiety in a woman’s late 30s or 40s, appearing without a clear psychological trigger, should prompt a progesterone measurement before any other intervention.

Bone Health

Progesterone stimulates osteoblast activity, the cells responsible for building new bone. Estrogen’s role in bone health is better known: it inhibits osteoclasts, the cells that break bone down. The two hormones work in complementary fashion. Estrogen prevents excessive bone resorption. Progesterone promotes bone formation.

A woman receiving estrogen alone is addressing only half of the bone metabolism equation. Adding progesterone supports the anabolic side, encouraging new bone deposition alongside the prevention of loss.

Neuroprotection

Progesterone and its metabolites have demonstrated neuroprotective properties in preclinical research. Allopregnanolone supports myelin repair, reduces neuroinflammation, and promotes neurogenesis in the hippocampus. Clinical research is still evolving, but the mechanistic basis for progesterone’s role in brain health is well established.

The cognitive fog that many women experience in perimenopause may involve progesterone decline alongside estrogen fluctuation. Addressing both hormones produces a more complete cognitive response than addressing either alone.

Breast Health

The distinction between bioidentical progesterone and synthetic progestins is particularly consequential when it comes to breast tissue.

The French E3N cohort study, which followed over 80,000 postmenopausal women, found that estrogen combined with micronized (bioidentical) progesterone did not increase breast cancer risk, while estrogen combined with synthetic progestins did. This is one of the largest and longest observational studies on the topic.

The REPLENISH trial, a more recent clinical trial evaluating a combined estradiol-progesterone formulation, confirmed the safety and tolerability of bioidentical progesterone in postmenopausal women.

The molecular distinction matters. Bioidentical progesterone activates the progesterone receptor selectively. Synthetic progestins, such as medroxyprogesterone acetate, have off-target activity on other steroid receptors, including the androgen and glucocorticoid receptors. This off-target activity likely accounts for the divergence in safety profiles.

Why Progesterone Declines First

Progesterone is produced primarily by the corpus luteum after ovulation. As a woman approaches perimenopause, ovulatory frequency decreases. Anovulatory cycles, in which a follicle develops and estrogen rises but ovulation does not occur, become more common.

In an anovulatory cycle, no corpus luteum forms, and no progesterone surge occurs. The result is a relative estrogen excess (sometimes called estrogen dominance) that can produce heavy periods, breast tenderness, bloating, irritability, and mood instability.

This phase, where progesterone has declined but estrogen is still being produced (often erratically), can persist for years. It explains why women in early perimenopause often feel worse, not better, and why their symptoms do not conform to the classic menopause narrative of estrogen deficiency.

The Case for Early Progesterone Support

Recognizing that progesterone declines before estrogen changes how perimenopause is managed.

A woman in her early 40s with disrupted sleep, new anxiety, heavier periods, and cycle irregularity may not need estrogen yet. She may need progesterone. Cyclic micronized progesterone, given during the luteal phase or nightly for sleep support, can address these symptoms directly.

This early intervention is both therapeutic and diagnostic. If symptoms improve with progesterone, the clinical suspicion is confirmed. The patient benefits from treatment while avoiding unnecessary investigations or inappropriate prescriptions.

Bioidentical Progesterone in Practice

Micronized progesterone is available as a commercially manufactured product (Prometrium) and through compounding pharmacies in capsule, cream, troche, or suppository form.

Oral micronized progesterone is the most commonly prescribed form. When taken at bedtime, its sedative effect (via allopregnanolone conversion) supports sleep while providing systemic progesterone levels. For women who experience gastrointestinal side effects with oral dosing, vaginal or transdermal routes offer alternatives.

Compounded progesterone allows for precise dose customization, which is particularly useful during the titration phase when the optimal dose is being established.

What Assessment Looks Like

Progesterone measurement should be timed to the menstrual cycle when a woman is still cycling. A serum progesterone drawn on day 19 to 21 of the cycle (approximately 5 to 7 days after expected ovulation) reflects luteal phase production. A low level at this time confirms anovulation or insufficient luteal function.

In women who are no longer cycling regularly, the clinical picture and symptom pattern guide the decision to initiate progesterone, with blood work confirming the response to treatment.

At Manus Solis, progesterone is assessed as part of the baseline Pulsus evaluation and tracked longitudinally alongside estradiol, testosterone, thyroid markers, and metabolic indicators. The Sensus domain captures the symptoms that progesterone directly influences: sleep quality, anxiety levels, mood stability, and menstrual pattern. Metabolic function, including insulin sensitivity and body composition patterns, is evaluated through the Virtus assessment. Progesterone’s effect on sleep quality has downstream effects on mitochondrial health and metabolic function that extend beyond sleep itself.

Treating progesterone in isolation is sometimes sufficient. More often, it is the first step in a comprehensive hormonal optimization strategy that evolves as the patient moves through the menopausal transition.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Perimenopause: The Symptoms Most Women Don’t Recognize
• Can’t Sleep? The Hormonal Explanation
• Birth Control Is Not HRT

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario pharmacy partner. To learn more or book a virtual consultation, visit manussolis.ca.